Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin-Reference-Cited by-同舟云学术

Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin

Published:2020-09 Issue:22 Volume:126 Page:4936-4947
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hassan Raffit¹^ORCID,Alewine Christine²,Mian Idrees¹,Spreafico Anna³,Siu Lillian L.³,Gomez‐Roca Carlos⁴,Delord Jean‐Pierre⁴,Italiano Antoine⁵⁶,Lassen Ulrik⁷⁸,Soria Jean‐Charles⁹¹⁰,Bahleda Rastilav⁹,Thomas Anish¹¹^ORCID,Steinberg Seth M.¹²,Peer Cody J.¹³,Figg William D.¹³¹⁴,Niederfellner Gerhard¹⁵,Méresse Naegelen Valérie¹⁶,Pastan Ira²

Affiliation:

1. Thoracic and GI Malignancies Branch Center for Cancer Research National Cancer InstituteNational Institutes of Health Bethesda Maryland

2. Laboratory of Molecular Biology Center for Cancer Research National Cancer InstituteNational Institutes of Health Bethesda Maryland

3. Division of Medical Oncology and Hematology Princess Margaret Cancer Centre University Health NetworkUniversity of Toronto Toronto Ontario Canada

4. Clinical Research Unit IUCT‐Oncopole Toulouse France

5. Department of Medicine Bergonie Institute Bordeaux France

6. Faculty of Medicine University of Bordeaux Bordeaux France

7. Department of Oncology Rigshospitalet Copenhagen Denmark

8. Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

9. Gustave Roussy Institute Villejuif France

10. University of Paris–South Orsay France

11. Developmental Therapeutics Branch Center for Cancer Research National Cancer InstituteNational Institutes of Health Bethesda Maryland

12. Biostatistics and Data Management Section Center for Cancer Research National Cancer InstituteNational Institutes of Health Bethesda Maryland

13. Clinical Pharmacology Program Center for Cancer Research National Cancer InstituteNational Institutes of Health Bethesda Maryland

14. Genitourinary Malignancies Branch Center for Cancer Research National Cancer InstituteNational Institutes of Health Bethesda Maryland

15. Beoro Therapeutics GmbH Seefeld Germany

16. Pharma Research and Early Development, Roche Innovation Center Basel Switzerland

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33145

Reference35 articles.

1. In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

2. Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy

3. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium

4. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

5. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE);Argani P;Clin Cancer Res,2001

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of mesothelin gene expression in dogs and overexpression in canine mesotheliomas;Frontiers in Veterinary Science;2024-09-09

2. Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review;Current Oncology Reports;2024-07-27

3. An epidermal growth factor receptor‐targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer;The FASEB Journal;2024-07

4. X-ray imageable, drug-loaded hydrogel that forms at body temperature for image-guided, needle-based locoregional drug delivery;Scientific Reports;2024-06-10

5. Targeted Therapy in Mesotheliomas: Uphill All the Way;Cancers;2024-05-22